Craig L Slingluff, Jr
Craig L Slingluff, Jr sponsors 23 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 14 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 3 trials.
Trial Pipeline
23 total, page 1 of 1
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NCT05839912
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT04364230
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
NCT04116320
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
NCT03617328
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
NCT02515227
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
NCT02382549
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
NCT02425306
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
NCT02385669
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
NCT02126579
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
NCT01846143
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
NCT01585350
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
NCT01532960
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
NCT01425749
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
NCT00977145
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
NCT00892567
Vaccine Therapy in Treating Patients With Advanced Melanoma
NCT00705640
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00373217
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00118274
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00118313
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
NCT00089193
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer
NCT00091286
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
NCT00938223
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
NCT00912418
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 3 |
Therapeutic Areas
What the Pipeline for Craig L Slingluff, Jr Shows
According to the ClinicalTrials.gov registry, Craig L Slingluff, Jr is linked to 23 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting, about 4% of the sponsor's indexed portfolio, and 14 are already marked complete, representing roughly 61% of the total.
The phase mix for Craig L Slingluff, Jr reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 21 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Craig L Slingluff, Jr is Melanoma with 3 linked trials, and 4 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.